Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Ironwood Pharmaceuticals ...

    NASDAQ: IRWD · Real-Time Price · USD
    0.68
    -0.02 (-3.08%)
    At close: Jun 23, 2025, 3:59 PM
    0.68
    1.03%
    Pre-market: Jun 24, 2025, 07:02 AM EDT
    -3.08%
    Bid 0.68
    Market Cap 109.62M
    Revenue (ttm) 317.68M
    Net Income (ttm) -31.41M
    EPS (ttm) -0.19
    PE Ratio (ttm) -3.57
    Forward PE 2.02
    Analyst Hold
    Ask 0.75
    Volume 1,243,582
    Avg. Volume (20D) 3,273,372
    Open 0.70
    Previous Close 0.70
    Day's Range 0.66 - 0.72
    52-Week Range 0.53 - 7.11
    Beta 0.23

    About IRWD

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IRWD
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IRWD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Ironwood Pharmaceuticals Inc. is scheduled to release its earnings on Aug 7, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    2 months ago
    -31.48%
    Ironwood Pharmaceuticals shares are trading lower ... Unlock content with Pro Subscription
    4 months ago
    -38.17%
    Ironwood Pharmaceuticals shares are trading lower. The company board announced approval for a 50% reduction in the workforce.
    news image

    2 weeks ago · zacks.com

    Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?

    Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

    news image

    1 month ago · zacks.com

    IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates

    Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.

    news image

    1 month ago · zacks.com

    Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates

    Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.

    news image

    1 month ago · businesswire.com

    Ironwood Pharmaceuticals Reports First Quarter 2025 Results

    BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...

    news image

    1 month ago · zacks.com

    Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for

    Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · businesswire.com

    Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

    BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7t...

    news image

    1 month ago · businesswire.com

    Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

    BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...

    news image

    2 months ago · businesswire.com

    Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

    BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and r...

    news image

    2 months ago · zacks.com

    Ironwood Shares Tank on Regulatory Update for Apraglutide

    Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.

    news image

    2 months ago · benzinga.com

    Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

    Ironwood Pharmaceuticals, Inc.  IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intest...

    Add to Watchlist